Next earnings date: 13 Aug 2025

CytoDyn Inc. – OTC:CYDY

Add to watchlist

$0.292

+0.17

+153.61%

Market closed

Open in about 19 hours

-17.86%

month

-17.86%

quarter

-37.23%

year

Market Cap	220.73M
Enterprise value	224.95M

P/E	-1.29
EV/Sales	5486.82
EV/EBITDA	-1.25
Price/Sales	4442.75
Price/Book	-1.57
PEG ratio	0.03
EPS	-0.20

Revenue	N/A
EBITDA	-41.10M
Income	-156.86M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-465275.61%
Oper. margin	-239980.49%
Gross margin	0%
EBIT margin	-239980.49%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

CytoDyn Inc. (OTC:CYDY): Profit margin
May 2022	0	-110.43M
Feb 2023	0	-15.87M
May 2023	0	-18.63M
Feb 2024	0	-11.92M

CytoDyn Inc. (OTC:CYDY): Payout ratio
Payout ratio	0%

CytoDyn Inc. (OTC:CYDY): Dividend Yield
2020
2021	0.02%
2022
2023
2024

CytoDyn Inc. (OTC:CYDY): Debt to assets
Nov 2022	7074000	123.04M	1739.37%
Feb 2023	14642000	121.65M	830.84%
May 2023	11292000	120.79M	1069.72%
Feb 2024	10270000	129.65M	1262.43%

CytoDyn Inc. (OTC:CYDY): Cash Flow
May 2022	-6.04M	30K	7.88M
Feb 2023	-6.21M	0	14.72M
May 2023	-3.41M	0	1.35M
Feb 2024	-2.33M	0	3.63M

CytoDyn alternative data

CytoDyn Inc. (OTC:CYDY): Employee count
Aug 2023	23
Sep 2023	23
Oct 2023	12
Nov 2023	12
Dec 2023	12
Jan 2024	12
Feb 2024	12
Mar 2024	12
Apr 2024	12
May 2024	12
Jun 2024	12
Jul 2024	12

CytoDyn
Hedge Funds Holdings Q1 2023

0.03% -0.04%

of CYDY is owned by hedge funds

8 -4

hedge funds hold CYDY stock

216.48K -281.21K

shares is hold by hedge funds

CYDY hedge funds holdings changes

CytoDyn Inc. (OTC:CYDY): Insider trades (number of shares)
Period	Buy	Sel
Jan 2020	501000	0
Apr 2020	0	2219837
May 2020	250000	3801337
Oct 2020	130000	0
Nov 2020	193500	0
Dec 2020	0	1816600

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	23 Sep 2021	NAYDENOV JORDAN G director director	Common Stock	266,668	$0.75	$200,001
Option	23 Sep 2021	NAYDENOV JORDAN G director director	Warrant (Right to Buy)	266,668	$0.75	$200,001
Option	23 Sep 2021	NAYDENOV JORDAN G director director	Common Stock	133,332	$0.75	$99,999
Option	23 Sep 2021	NAYDENOV JORDAN G director director	Common Stock	888,888	$0.45	$400,000
Option	5 Feb 2021	KELLY SCOTT A. director, officer: Chairman & CMO director, officer: Chairman & CMO	Common Stock	166,000	$0.75	$124,500
Option	22 Dec 2020	MULHOLLAND MICHAEL D. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	150,000	$0.9	$135,000
Sale	22 Dec 2020	MULHOLLAND MICHAEL D. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	12,100	$7	$84,700
Sale	22 Dec 2020	MULHOLLAND MICHAEL D. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	453,997	$6.62	$3,003,190
Option	22 Dec 2020	MULHOLLAND MICHAEL D. officer: Chief Financial Officer officer: Chief Financial Officer	Non-qualified Stock Option (right to buy)	161,801	$0.87	$140,767
Sale	22 Dec 2020	MULHOLLAND MICHAEL D. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	245,704	$5.49	$1,349,898

CytoDyn
Executives

Insider	Age	Compensation
Dr. Nader Z. Pourhassan Ph.D. (1963) Chief Executive Officer, Pres & Director	62	$2,060,000
Dr. Scott A. Kelly FAAPMR, M.D. (1970) Chairman, Chief Medical Officer & Head of Bus. Devel.	55	$1,050,000
Dr. Nitya G. Ray Ph.D. (1953) Chief Operating Officer & Chief Technology Officer	72	$797,500

CytoDyn
Latest News

Tuesday, 17 December 2024
08:30	December 2024 Letter to Shareholders	globenewswire.com
Monday, 4 November 2024
08:30	CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial	globenewswire.com
Wednesday, 30 October 2024
08:30	CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories	globenewswire.com
Monday, 7 October 2024
11:05	CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques	globenewswire.com
Friday, 4 October 2024
08:30	CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial	globenewswire.com
Tuesday, 24 September 2024
08:30	CytoDyn Announces Preliminary Findings in Study with SMC Laboratories	globenewswire.com
Monday, 9 September 2024
08:30	September 2024 Letter to Shareholders	globenewswire.com
Friday, 23 August 2024
08:30	CytoDyn Engages Leading CRO For Phase II Inflammation Trial	globenewswire.com
Monday, 12 August 2024
08:30	CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer	globenewswire.com
Tuesday, 9 July 2024
08:30	CytoDyn Announces Settlement with Amarex Clinical Research LLC	globenewswire.com
Thursday, 27 June 2024
08:30	CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024	globenewswire.com
Tuesday, 28 May 2024
08:30	CytoDyn to Host Webcast to Provide Company Update	globenewswire.com
Thursday, 16 May 2024
08:30	May 2024 Letter to Shareholders	globenewswire.com
Thursday, 29 February 2024
08:30	CytoDyn Announces FDA Has Lifted Clinical Hold	globenewswire.com
Thursday, 1 February 2024
08:30	CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma	globenewswire.com
Monday, 29 January 2024
08:30	CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO	globenewswire.com
Thursday, 18 January 2024
11:11	SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CytoDyn Inc. (OTC: CYDY)	prnewswire.com
Thursday, 7 December 2023
16:00	CytoDyn Announces Webcast to Provide Company Update	GlobeNewsWire
Tuesday, 11 July 2023
16:05	CytoDyn Announces Company Updates and Investment Community Update Webcast	GlobeNewsWire
Wednesday, 5 April 2023
08:30	CytoDyn to Hold Webcast to Provide a Company Update	GlobeNewsWire
Friday, 23 December 2022
08:00	CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO	GlobeNewsWire
Wednesday, 21 December 2022
15:30	Former CytoDyn CEO and clinical trial associate indicted for defrauding investors	GeekWire
Monday, 17 October 2022
09:36	CytoDyn: Repositioning And Refocusing With New Leadership	Seeking Alpha
Monday, 19 September 2022
08:30	CytoDyn to Hold Webcast to Provide a Quarterly Company Update	GlobeNewsWire
Wednesday, 24 August 2022
16:25	CytoDyn: It Only Takes One Hit	Seeking Alpha
Wednesday, 22 June 2022
08:30	CytoDyn to Hold Webcast to Provide a Quarterly Company Update	GlobeNewsWire
Monday, 13 June 2022
18:04	CytoDyn: Nearly Impossible To Revive This Company	Seeking Alpha
Tuesday, 12 April 2022
11:24	CytoDyn touts publication of paper on suppression of human and simian immunodeficiency virus replication with leronlimab	Proactive Investors
Wednesday, 30 March 2022
15:52	CytoDyn: Holding Onto The Ruins From An End Of An Era	Seeking Alpha
08:30	CytoDyn to Hold Webcast to Provide Company Update	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 17 Oct 2022

CytoDyn: Repositioning And Refocusing With New Leadership
Seeking Alpha 24 Aug 2022

CytoDyn: It Only Takes One Hit
Seeking Alpha 13 Jun 2022

CytoDyn: Nearly Impossible To Revive This Company
Seeking Alpha 30 Mar 2022

CytoDyn: Holding Onto The Ruins From An End Of An Era

Frequently Asked Questions (FAQ)

What's the price of CytoDyn stock today?

One share of CytoDyn stock can currently be purchased for approximately $0.29.
When is CytoDyn's next earnings date?

CytoDyn Inc. is estimated to report earnings on Wednesday, 13 Aug 2025.
Does CytoDyn pay dividends?

No, CytoDyn does not pay dividends.
How much money does CytoDyn make?

CytoDyn has a market capitalization of 220.73M.
What is CytoDyn's stock symbol?

CytoDyn Inc. is traded on the OTC under the ticker symbol "CYDY".
What is CytoDyn's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of CytoDyn?

Shares of CytoDyn can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are CytoDyn's key executives?
CytoDyn's management team includes the following people:
- Dr. Nader Z. Pourhassan Ph.D. Chief Executive Officer, Pres & Director(age: 62, pay: $2,060,000)
- Dr. Scott A. Kelly FAAPMR, M.D. Chairman, Chief Medical Officer & Head of Bus. Devel.(age: 55, pay: $1,050,000)
- Dr. Nitya G. Ray Ph.D. Chief Operating Officer & Chief Technology Officer(age: 72, pay: $797,500)
How many employees does CytoDyn have?

As Jul 2024, CytoDyn employs 12 workers.
When CytoDyn went public?

CytoDyn Inc. is publicly traded company for more then 19 years since IPO on 17 Nov 2005.
What is CytoDyn's official website?

The official website for CytoDyn is cytodyn.com.
Where are CytoDyn's headquarters?

CytoDyn is headquartered at 1111 Main Street, Vancouver, WA.
How can i contact CytoDyn?

CytoDyn's mailing address is 1111 Main Street, Vancouver, WA and company can be reached via phone at +36 09808524.

CytoDyn Inc.

cytodyn.com

Exchange:

OTC

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease ("COVID-19"). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

+36 09808524

1111 Main Street
Vancouver, WA 98660

CIK: 0001175680
ISIN: US23283M1018
: